论文部分内容阅读
目的检测伊马替尼治疗前后的慢性粒细胞白血病(CML)患者VEGF质量浓度,研究血管内皮生长因子(VEGF)在CML中的表达及临床意义,探讨VEGF对伊马替尼治疗CML疗效判定的价值。方法2003-08～2005-02中国医科大学第一临床学院选择CML患者32例。伊马替尼治疗达血液学完全缓解12例。应用ELISA法检测血浆VEGF的表达质量浓度。结果32例患者血浆VEGF表达质量浓度为(296.16±18.19)ng/L,明显高于对照组(P<0.01)。伊马替尼治疗达血液学完全缓解的CML患者的VEGF质量浓度为(198.23±16.51)ng/L,明显低于治疗前(P<0.05)。结论CML患者血浆VEGF表达明显增高。血浆VEGF可能成为判定伊马替尼疗效的一个指标。
Objective To detect the levels of VEGF in patients with chronic myeloid leukemia (CML) before and after imatinib treatment and to investigate the expression and clinical significance of vascular endothelial growth factor (VEGF) in CML. To investigate the effect of VEGF on the efficacy of imatinib in CML value. Methods Thirty - two CML patients were selected from the First Clinical College of China Medical University from August 2003 to February 2005. Imatinib treatment of hematology complete remission in 12 cases. The plasma concentration of VEGF was detected by ELISA. Results The plasma concentration of VEGF in the 32 patients was (296.16 ± 18.19) ng / L, which was significantly higher than that in the control group (P <0.01). The level of VEGF in CML patients with imatinib treatment of hematologic complete remission was (198.23 ± 16.51) ng / L, which was significantly lower than that before treatment (P <0.05). Conclusion The expression of VEGF in plasma of CML patients is obviously increased. Plasma VEGF may be an indicator of the efficacy of imatinib.